Please login to the form below

Not currently logged in
Email:
Password:

Zinfandel

This page shows the latest Zinfandel news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and

Latest news

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimer’s drug

    Pioglitazone failed to show therapeutic improvements in late-stage testing. A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics after it ... Takeda joined forces with Zinfandel on

  • Takeda continues Actos resurrection as Alzheimer's drug Takeda continues Actos resurrection as Alzheimer's drug

    Late-stage trial will see if pioglitazone can delay disease progression. Takeda and partner Zinfandel Pharma have started a phase III trial of pioglitazone in people at risk of developing the ... Earlier studies of pioglitazone in symptomatic AD patients

  • Non-amyloid therapies emerging for Alzheimer's at AAIC Non-amyloid therapies emerging for Alzheimer's at AAIC

    Takeda and Zinfandel Pharmaceuticals highlighted a new approach to identifying individuals who are at risk of developing Alzheimer's dementia which could be used to support clinical trials of early treatments.

  • Creative partnerships

    Preclinical. 100. Zinfandel Pharma/Takeda. TOMM40 assay, biomarker for risk of developing Alzheimer's disease.

  • Takeda signs Alzheimer's deal for Actos

    Under the partnership deal, Takeda has licensed the rights to an assay from the small US company Zinfandel Pharmaceuticals that it plans to use to identify high-risk older adults who ... The biomarker is being developed by Zinfandel to identify healthy

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...